WuXi AppTec’s sales are becoming even more increasingly dependent on the US despite the service provider not yet fully shaking off concerns over its ties

Parkinson’s stem cell therapy developer Oryon Cell Therapies started out Monday morning with three announcements: It enlisted Ron Cohen as its new CEO, netted an

Plus, news about Opdivo: 📊 Dizal drug succeeds in Phase 3 lung cancer study: The drug Zegfrovy improved progression-free survival compared to chemo in first-line

Sanofi has licensed rights to Kali’s trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.